Angle PLC - Guildford, England-based liquid biopsy company - Says new study, from Health Research Institute of Santiago in Spain, demonstrates use of company's Parsortix to assess PD-L1 circulating tumor cells in patients with cancer.
Chief Executive Andrew Newland says: "Angle is pleased to see continued efforts being made to better identify patients who will respond well to immune checkpoint inhibitors. Whilst ICIs have revolutionised metastatic non-small cell lung cancer patient care, they are costly and associated with significant side effects.
"We have made substantial progress in the development of our Parsortix-based PD-L1 assay and are offering this to our pharma services customers. In addition, we are planning to investigate its utility in guiding immunotherapy treatments with the aim of offering the assay as a laboratory developed test from our clinical laboratories for patient management."
Current stock price: 118.00 pence
Year-to-date change: up from 47.75p
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserve.
Angle (AGL)